Letter by Kielstein et al regarding article, "high-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid" [3]

Circulation

Volumn 115, Issue 18, 2007, Pages

  Kielstein, Jan T ^a   Woywodt, Alexander ^b   Salpeter, Shelley R ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; OXIPURINOL; URIC ACID;

CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; HYPERKALEMIA; KIDNEY CLEARANCE; KIDNEY FAILURE; KIDNEY FUNCTION; LETTER; OXIDATIVE STRESS; PRIORITY JOURNAL; UNITED STATES;

ALLOPURINOL; GLOMERULAR FILTRATION RATE; HEART FAILURE, CONGESTIVE; HUMANS; KIDNEY; KIDNEY DISEASES; OXYPURINOL; URIC ACID;

EID: 34248202139     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.106.683831     Document Type: Letter

References (5)

1. George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006;114:2508-2516.
2. Brosius FC 3rd, Hostetter TH, Kelepouris E, Mitsnefes MM, Moe SM, Moore MA, Pennathur S, Smith GL, Wilson PW; American Heart Association Kidney and Cardiovascular Disease Council; Council on High Blood Pressure Research; Council on Cardiovascular Disease in the Young; Council on Epidemiology and Prevention; Quality of Care and Outcomes Research Interdisciplinary Working Group. Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney And Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: developed in collaboration with the National Kidney Foundation. Circulation. 2006;114:1083-1087.
3. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76:47-56.
4. Kumar A, Edward N, White MI, Johnston PW, Catto GR. Allopurinol, erythema multiforme, and renal insufficiency. BMJ. 1996;312:173-174.
5. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543-551.